Christine E. Jones, BMBS, PhD - A Full-Throated Appeal to Personalize Care in Advanced Gastroesophageal Junction (GEJ) and Esophageal Cancers: Where Do Immunotherapy-Based Regimens Fit In?

Please visit answersincme.com/VKP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in medical oncology discusses patient profiles, disease factors, and other ways to optimize treatment of patients with advanced gastroesophageal junction and esophageal cancers. Upon completion of this activity, participants should be better able to: Describe the clinical profiles of first-line immunotherapy-based combination regimens for the management of patients with advanced gastroesophageal junction (GEJ) and esophageal cancers; Identify clinical and disease factors that can be used to personalize first-line treatment selection for patients with advanced GEJ and esophageal cancers; and Review clinical strategies to optimize quality of care for patients with advanced GEJ and esophageal cancers on immunotherapy-based combination regimens.